Immunome presents pipeline update; cash runway into Q1 2026; 177Lu-FAP IND planned 1Q25

Immunome Inc.

Cash runway expected into Q1 2026; recently completed $125M PIPE with leading healthcare investors.
Lead programs: first-in-class anti-IL-38 mAb and FAP-targeted radioligand therapy (177Lu-FAP).
IND filing for 177Lu-FAP anticipated in Q1 2025; preclinical data show single-dose antitumor activity.
Pipeline includes ADC strategy centered on novel targets; 70 antibody-target pairs identified to date.
Management team led by former Seagen CEO Clay Siegall; headquarters in Bothell, WA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.